Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study In Patients With Kidney Cancer Treated With Sutent

Completed

Conditions: Advanced or Metastatic Renal Cell Carcinoma
Renal Cancer

Interventions: Drug: Sutent

First Posted Date: 2009-04-01

Last Posted Date: 2012-11-09

Lead Sponsor: Pfizer

Target Recruit Count: 121

Registration Number: NCT00873210

Locations: 🇸🇰
Pfizer Investigational Site, Zilina, Slovakia

Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan

Phase 3

Completed

Conditions: Pelvic Inflammatory Disease

Interventions: Drug: Azithromycin

First Posted Date: 2009-03-30

Last Posted Date: 2011-11-03

Lead Sponsor: Pfizer

Target Recruit Count: 76

Registration Number: NCT00871494

Locations: 🇯🇵
Pfizer Investigational Site, Okayama-city, Japan

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Inotuzumab Ozogamicin (CMC-544)

First Posted Date: 2009-03-25

Last Posted Date: 2017-10-31

Lead Sponsor: Pfizer

Target Recruit Count: 81

Registration Number: NCT00868608

Locations: 🇺🇸
New York Medical College, Hawthorne, New York, United States
🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 39 locations

Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Biological: Xyntha

First Posted Date: 2009-03-25

Last Posted Date: 2025-06-12

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT00868530

Locations: 🇨🇳
Pfizer Investigational Site, Shanghai, China

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma, B-Cell

Interventions: Drug: inotuzumab ozogamicin (CMC-544)
Drug: rituximab

First Posted Date: 2009-03-23

Last Posted Date: 2017-12-05

Lead Sponsor: Pfizer

Target Recruit Count: 64

Registration Number: NCT00867087

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇫🇷
CHU Saint-Eloi, Montpellier Cedex 5, France

and more 30 locations

A Study to Estimate the Time Course of PF-00241939 Concentration in the Blood Following Dosing by Oral Inhalation From Dry Powder Inhalers

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Treatment A
Drug: Treatment B

First Posted Date: 2009-03-23

Last Posted Date: 2009-07-28

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00867282

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: PF03635659

First Posted Date: 2009-03-19

Last Posted Date: 2009-03-23

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT00864786

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip

Phase 3

Terminated

Conditions: Osteoarthritis

Interventions: Biological: tanezumab
Drug: diclofenac
Other: IV placebo

First Posted Date: 2009-03-18

Last Posted Date: 2021-02-26

Lead Sponsor: Pfizer

Target Recruit Count: 607

Registration Number: NCT00864097

Locations: 🇦🇹
Nuhr Zentrum, Senftenberg, Austria
🇦🇹
ClinPharm International GmbH, Wien, Austria
🇦🇹
Medizinische Universitaet Wien/AKH, Wien, Austria

and more 70 locations

Tanezumab and Nerve Function In Arthritis Patients

Phase 3

Terminated

Conditions: Osteoarthritis

Interventions: Biological: tanezumab
Other: Placebo

First Posted Date: 2009-03-18

Last Posted Date: 2021-02-04

Lead Sponsor: Pfizer

Target Recruit Count: 220

Registration Number: NCT00863772

Locations: 🇺🇸
Jefrey D. Lieberman, MD, Decatur, Georgia, United States
🇺🇸
Foundation for Southwest Orthopedic Research, Houston, Texas, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 92 locations

Tanezumab in Osteoarthritis of the Hip or Knee (2)

Phase 3

Completed

Conditions: Osteoarthritis

Interventions: Biological: tanezumab 10 mg
Biological: tanezumab 5 mg
Drug: naproxen
Other: placebo

First Posted Date: 2009-03-17

Last Posted Date: 2021-05-17

Lead Sponsor: Pfizer

Target Recruit Count: 849

Registration Number: NCT00863304

Locations: 🇺🇸
HeartCare Research, Sarasota, Florida, United States
🇺🇸
Spring Clinical Research, Sugar Land, Texas, United States
🇺🇸
Sugar Land Med-Ped, P.A., Sugar Land, Texas, United States

and more 91 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy